SCOR renews its contingent capital program Press release18 December 2025 - N° 20 SCOR renews its contingent capital program Disclaimer: SCOR (hereafter “SCOR” or the “Company”) has implemented a contingent capital program in the form of share subscription warrants with J.P. Morgan SE, which upon exercise of these warrants after having received the issued shares is not intended to remain a shareholder of the Company. The Company's ordinary shares, which would result from the exercise of the aforementioned share subscription warrants, will likely be sold on the market very shortly, w...
SCOR renouvelle son mécanisme de capital contingent Communiqué de presse18 décembre 2025 - N° 20 SCOR renouvelle son mécanisme de capital contingent Avertissement : SCOR (ci-après « SCOR » ou la « Société ») a mis en place un mécanisme de capital contingent sous forme de bons d’émission d’actions avec la société J.P. Morgan SE, qui, en cas d’exercice de ces bons, après avoir reçu les actions ordinaires émises, n’a pas vocation à rester actionnaire de la Société. Les actions ordinaires de la Société, qui résulteraient de l’exercice des bons d’émission d’actions susvisés, seront, probab...
Based on various press articles, it seems increasingly likely that the European Union is to abandon the earlier agreed ban on new combustion engine-based passenger cars by 2035, whilst new legislation would still require a significant reduction of tailpipe emissions. Any loosening of legislation would probably be good news for Umicore's Catalysts business, with European ICE Light duty Automotive Catalysts' revenue representing c. 28% of total ICE light duty Automotive Catalysts' revenue. We awai...
EUR 400 million share buyback completed Schiphol, December 16, 2025 - Aegon announces today the successful completion of its share buyback program, which initially began on July 1, 2025, as a EUR 200 million initiative and was later expanded, on August 25, 2025, by an additional EUR 200 million, bringing the total to EUR 400 million. Between July 1, 2025, and December 15, 2025, 61,197,437 common shares were repurchased for a total amount of EUR 400 million at an average price of EUR 6.4772 per share. Aegon will cancel the repurchased shares in December 2025. For further details, visit our...
SCOR’s Actuarial Awards reward outstanding research across six countries in 2025 Press release15 December 2025 - N° 19 SCOR’s Actuarial Awards reward outstanding research across six countries in 2025 Each year for almost 30 years, SCOR has rewarded the best research in the field of actuarial science with prizes in several countries. These prizes are designed to promote the development of actuarial science, to encourage research in this field, and to contribute to the improvement of risk knowledge and management. The SCOR Actuarial Awards are recognized in the insurance and reinsuranc...
Les prix SCOR de l’actuariat récompensent des travaux de recherche exceptionnels dans six pays en 2025 Communiqué de presse15 décembre 2025 - N° 19 Les prix SCOR de l’actuariat récompensent des travaux de recherche exceptionnels dans six pays en 2025 Chaque année depuis presque 30 ans, SCOR récompense les meilleurs travaux de recherche dans le domaine de l’actuariat en attribuant des prix dans plusieurs pays. Ces prix ont pour but de promouvoir le développement de la science actuarielle, d’encourager la recherche dans ce domaine et de contribuer à faire progresser la connaissance et l...
A director at Compagnie Financiere Richemont S.A. sold 1,062 shares at 169.772CHF and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
Novartis breaks ground on flagship manufacturing hub in North Carolina FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to ensure end-to-end manufacturing of all key medicines for US patients in the US at scaleGroundbreaking marks continuation of Novartis investment and growth in the US, capping year of significant regulatory and manufacturing milestones East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company...
Aegon Capital Markets Day 2025 – The Next Frontier Strategic highlights: Aegon announces ambition to become a leading US life insurance and retirement group Aegon to move its head office and legal seat to the US and be renamed Transamerica Inc. at completion of transition, which Aegon aims to conclude by January 1, 2028Aegon Asset Management to focus on growing third-party revenues and improving efficiencyContinued focus on profitable growth in Aegon’s International business Strategic review of Aegon UK, evaluating all options, including divestment Financial highlights: Achieving all fi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.